Pharmacodynamic Measurements of Immunosuppression in Healthy Individuals: A Comparison of the Tuberculin Skin Test and Tuberculin-Stimulated Lymphocyte Proliferation in Whole Blood

Authors: Singh D.1; Woodcock A.1; Booth G.2

Source: International Journal of Pharmaceutical Medicine, Volume 17, Numbers 3-4, 2003 , pp. 131-136(6)

Publisher: Adis International

Buy & download fulltext article:

OR

Price: $57.95 plus tax (Refund Policy)

Abstract:

Objectives: Studies of novel immunosuppressive agents using small numbers of healthy volunteers require validated methods for detecting pharmacodynamic effects. We investigated the ability of tuberculin-stimulated lymphocyte proliferation in whole blood and the tuberculin skin test to assess immunosuppression in healthy volunteers.

Methods: This was a parallel-group, placebo-controlled study. Five weeks after a tuberculin test, 14 study participants received either placebo or prednisolone (30mg or 60mg) once daily for 7 days. Blood samples were collected before the first dose and at 2 hours post-first dose for assessment of lymphocyte proliferation. On day 5, a repeat skin test was administered.

Results: Lymphocyte proliferation was reduced in all ten study participants who received prednisolone (mean reduction: 30mg = 77.5%, 60mg = 77%; p < 0.01 compared with placebo) with no reduction in any of the placebo group. While prednisolone reduced skin test size in seven study participants, there was an increase in three participants and no overall significant effect compared with placebo (p > 0.05).

Conclusion: Lymphocyte proliferation in whole blood was able to detect pharmacological immunosuppression in healthy individuals, while the tuberculin skin test did not. This whole blood method may have applications for detecting the effects of novel compounds in future healthy volunteer studies.

Keywords: Immunosuppressants, pharmacodynamics; Pharmacodynamic modelling

Document Type: Research article

Affiliations: 1: 1 Medicines Evaluation Unit, North West Lung Research Centre, Wythenshawe, Manchester, UK 2: 2 Clinical Pharmacology and Respiratory and Inflammation Research Area, AstraZeneca, Alderley Park, Macclesfield, UK

Publication date: 2003-01-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page